LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate ...Middle East

Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

Read More Details
Finally We wish PressBee provided you with enough information of ( LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate )

Also on site :

• Term Sheet Next: How Facebook’s former chief revenue officer is coaching the next generation of startup founders
• Popular Dunkin’ Menu Item Gets a ‘Glow-Up’ in Limited-Edition Release
• Germany: Life imprisonment sentence for Syrian doctor Alaa Moussa